News
-
New product launch: APOHEALTH Terbinafine Cream 15g
Wednesday | Apr 30 2025APOHEALTH Terbinafine Cream 15g is an affordable alternative to Lamisil Cream 15g, which provides treatment of fungal skin infections such as athlete's foot, ringworm infections and cutaneous candidiasis.
-
Hartley’s Gripe Water
Wednesday | Apr 30 2025HARTLEY'S Gripe Water is a natural blend of herbal ingredients of dill seed oil, peppermint oil, chamomile and coriander oil.
-
PSA urges vaccination
Tuesday | Apr 29 2025WITH World Immunisation Week marked from 24-30 Apr 2025, the Pharmaceutical Society of Australia (PSA) is reminding Australians about the importance of staying up to date with vaccinations.
-
Booster vax side matters
Tuesday | Apr 29 2025AUSTRALIAN researchers have revealed why receiving a booster vaccine in the same arm as the first dose can generate a more effective immune response more quickly.
-
Hospital pharmacy: Built for the future
Tuesday | Apr 29 2025HOSPITAL pharmacy opens doors to a growing number of specialties, dynamic career paths, and a future contributing to team-based, multidisciplinary care - the direction of modern health care.
-
Webinar: VAD conversations
Tuesday | Apr 29 2025THE Advanced Pharmacy Australia (AdPha) WA Branch will be hosting an event on voluntary assisted dying (VAD) tonight from 5.30-7.00pm WST, in-person and online, for pharmacy practitioners.
-
Aussie data backs shingles vax benefit
Tuesday | Apr 29 2025AUSTRALIAN data has confirmed Welsh research (PD 03 Apr) finding that the herpes zoster (HZ) vaccine can reduce the risk of developing dementia.
-
ApoB test better for CVD risk
Tuesday | Apr 29 2025FOR almost 60 years, measuring cholesterol levels in the blood has been the best way to identify individuals at high risk of heart disease.
-
Dispensary Corner 29 Apr 25
Tuesday | Apr 29 2025THAT trendy oat milk latte might not be as healthy as TikTok has led you to believe.
-
PBS nasal antidepressant
Monday | Apr 28 2025FROM 01 May, Spravato nasal spray (esketamine) will be available through the Pharmaceutical Benefits Scheme (PBS) for adults with depression that has not responded adequately to at least two different antidepressants.
